#ChronicIllnessVoice | Pharma / Science / Tech / Digital / AI | A mix of news, events and Resources

Page 9


Industry Dive, Inc newsletters

Biopharma Dive Newsletter 25 May 2019

BROUGHT TO YOU BY — BioPharma Dive Brand Studio

Optimize Your Workflows with Better Data
How much data is too much? Many biotechs struggle with data overload, which can be detrimental in today’s competitive pharma landscape. Learn how new technologies can optimize your usage.

BioPharma Dive’s Top News | Weekender | May​ 25,​ 2019

Main Headline: Novartis gene therapy approved, but will come at cost of more than $2 million


Other headlines

5 novel immuno-oncology targets to know before ASCO

Novartis looking earlier for deals as biotech valuations stay high

SPONSORED CONTENT BY BIOPHARMA DIVE BRAND STUDIO
How do you choose the right CDMO partner?

UK charity sells Keytruda rights for $1.3B

Merck puts $1B more into oncology, with kidney cancer a focus

No news is bad news for Tocagen


UPCOMING EVENT

How to Choose the Best Partner for Your Biologic Development and Manufacturing | June 11, 2019 | Webinar 2 pm ET


Read all the above plus more via this button


Don’t forget that I subscribe for the newsletters that I share


Biopharma Dive Newsletter 14 May 2019


Sponsors of this edition of the newsletter

Reach New Heights with Catalent Biologics at BIO


Catalent to Acquire Gene Therapy Leader Paragon Bioservices

Catalent Biologics has entered into an agreement to acquire Paragon Bioservices, a leading viral vector development and manufacturing partner focused on the rapidly expanding gene therapy market.

Read all about the deal via the newsletter button link below to the Biopharma Newsletter 14 May 2019


WEBINAR: Planning Successful Launches of Complex Drug Products

Developing and bringing a new drug to market is a long, expensive and uncertain process. It’s even more complicated when it comes to complex products such as biologics.

Watch the webinar through clicking the link below to the Biopharma Newsletter 14 May 2019


Catalent Pharma Solutions respects your privacy.

Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent’s affiliation or endorsement or the website, its owner(s) or the content.

© 2019, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.


Read the above and get access to read more via this button


BioPharma Dive Weekender | May​ 11,​ 2019

Headlines


‘Stay tuned.’ Allergan CEO vows decisive action amid investor anger

Yet Brent Saunders offered few specifics on a path forward for Allergan, which recently staved off a challenge from activist investor Appaloosa.


Roche risdiplam data heats up SMA rivalry with Novartis

The oral agent looks like it could give gene therapy Zolgensma a run for its money.


Catalyst dives as FDA approves rival’s rare disease drug

Jacobus Pharmaceutical’s Ruzurgi is cleared for a different age range than Catalyst’s Firdapse, yet investors appear concerned about off-label use eroding the latter’s business.


SPONSORED CONTENT BY BIOPHARMA DIVE BRAND STUDIO
FDA guidance to using eConsent in clinical trials

Learn more about the FDA’s support of eConsent and where the future of biopharma trial consent is headed in our webinar. Watch now.


Drugmakers will soon be required to disclose prices in TV ads

Forcing pharma’s hand, the Trump administration finalized a proposal requiring list prices in DTC advertising, inviting a possible legal challenge from industry.


Pfizer to buy Therachon for $340M, taking on BioMarin, Ascendis

Therachon has advanced an experimental treatment for dwarfism through Phase 1 testing. Pfizer said they will take it from there.


Read the above news via this button link to the newsletter



BioPharma Dive is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won’t share your email address with anyone else without your permission.


Healthcare Dive weekender June​ 1,​ 2019

DOJ loses bid to change contours of CVS-Aetna settlement hearing

Provider groups slam rate setting in House surprise billing draft legislation

WannaCry malware still hitting healthcare organizations

Most hospitals don’t meet Leapfrog maternity care standards

Half of hospital boards lack succession plan


Read the articles above and more via the button link below


Healthcare Dive weekender May​ 25,​ 2019

BROUGHT TO YOU BY — IBM

Pinpoint Actionable Insights To Make Confident Decisions
Learn how better insights lead to confident decision making and see how IBM Watson Health is elevating performance. Read the case study.

Main Headline: UnitedHealth named most valuable healthcare brand


Other headlines

5 state AGs push judge to approve CVS-Aetna merger agreement

Q&A: Ascension’s chief community impact officer on providing care outside the hospital

No improvement in patient access to online health records, ONC finds

Private payers cover more than 40% of drug costs


UPCOMING EVENTS


The 4th Annual RISE Quality Leadership Summit – Qualipalooza

June 27, 2019 – June 28, 2019 | Orlando, FL


Read the articles above and more via the button link below


Don’t forget that I subscribe for the newsletters that I share



Healthcare Dive is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won’t share your email address with anyone else without your permission.


MedTech Dive Weekender June​ 1,​ 2019

 Vertex chooses its cystic fibrosis future Following positive late-stage readouts for two combination regimens, Vertex has selected the triplet it intends to file with regulators later this year. 
 Turning Point makes push to outdo Pfizer, Roche in targeted cancer therapy Fresh off an IPO, the San Diego biotech unveiled data on ASCO’s first day for repotrectinib, its challenger to Xalkori and entrectinib in a rare type of lung cancer. 
 As ASCO begins, Iovance shows progress with cancer cell therapy The biotech’s therapy, which uses tumor-infiltrating lymphocytes, has spurred responses in some patients with advanced melanoma and cervical cancer.  
 SPONSORED CONTENT BY LEE INDUSTRIES How to choose the right system for high-viscosity mixing This solution delivers fast, consistent mixing via double-motion scraped-surface agitation, counter-rotating mixing bars and a high-shear mixing head.Get the Guide. 
 PE firm nabs Vibalogics, banking on demand for complex viral products The deal brings 50 employees and a 27,000-square-foot manufacturing facility in Germany under the ownership of Ampersand Capital Partners. 
 Mitsubishi pulls EU application for ALS drug, citing ‘unwarranted’ data request Regulators had concerns that data from a key study that has helped Radicava in other markets isn’t strong enough to warrant approval in the bloc. 

Four steps to choosing the right CDMO partner In our webinar, hear from what industry experts believe are the four most important steps you can follow to assess and select the CDMO that fits your organization’s needs and aligns with your goals.


Read the articles above and more via the button link below


MedTech Dive Weekender May​ 25,​ 2019

BROUGHT TO YOU BY — PTC

Maximize medical device uptime with IoT
Explore how IoT technology is helping medical device manufacturers maximize device uptime by providing proactive service. Download the guide

Main headline: J&J’s Auris unveils early results on Monarch robot for lung procedures


Other headlines

Biotronik stent bests Medtronic in study of small-vessel lesions

Cook lands rights to sell single-use duodenoscope in US

LifeScan deal challenges Abbott, Dexcom for CGM market

Integra LifeSciences recall draws Class I label from FDA


Read the articles above and more via the button link below


Don’t forget I subscribe to all the newsletters that I share


Follow Medtech Dive on Twitter




Medtech Dive 14 May 2019
Brought to you by
ZS Associates

From Medtech Dive newsletter 14 May 2019
ZS Associates Header from newsletter Medtech Dive 14 May 2019
Image from MedTech Dive 14 May 2019

Medtech Leaders Discuss Vertical Integration and Hospital Centricity | Medtech Dive 14 May 2019


Strategic vertical integration can offer medtech companies a new path forward within a fluctuating healthcare landscape

Opening lines

Access this newsletter via this button link


MedTech Dive is a product of Industry Dive, Inc. 1575​ Eye St NW, Suite 400, Washington,​ DC 20005


Please remember that I subscribe to all the newsletters included in this magazine

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13


Page 9

2 thoughts on “#ChronicIllnessVoice | Pharma / Science / Tech / Digital / AI | A mix of news, events and Resources

Comments are closed.